Stent strut thickness and acute vessel injury during percutaneous coronary interventions: an optical coherence tomography randomized clinical trial

Coron Artery Dis. 2021 Aug 1;32(5):382-390. doi: 10.1097/MCA.0000000000000943.

Abstract

Aims: Compare the degree of acute vascular injury caused by a polymer-free, thin-strut drug-eluting stent (DES) to that caused by a bioresorbable polymer, thick-strut DES using optical coherence tomography (OCT).

Methods and results: Fifty patients requiring nonurgent PCI were randomized to receive either a thin or a thick-strut DES. OCT was performed before and after stent implantation. OCT-based injury score (IS) after implantation was numerically higher within thick-strut stents 0.32 vs. 0.23, but the difference was NS (P = 0.61). Edge dissections were present in 36% of the patients without differences between groups. Tissue prolapse (TP) area was larger with thin-strut stents (2.26 vs. 1.83 mm2, P = 0.04). Stent expansion and symmetry index were similar between the two platforms (85% vs. 94%, P = 0.08; and 0.82 vs. 0.80, P = 0.25). No differences were observed in total malapposition area (1.85 mm2 in thin-strut stents vs. 1.47 mm2, P = 0.48). Regarding the influence of plaque-type, IS tended to be higher (non-significant) with thick strut DES in fibrocalcific plaques. Stent malapposition area was smaller in fibrous plaques, especially with thin strut stents (P = 0.03).

Conclusion: There was no difference in the extent of OCT-based vessel injury associated with thin and thick-strut DES platforms. TP was larger with the thin strut DES, potentially reflecting a deeper stent embedment in the vessel wall.

Trial registration: ClinicalTrials.gov NCT03026465.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Biodegradable Plastics / pharmacology
  • Coronary Angiography / methods
  • Coronary Artery Disease / diagnosis
  • Coronary Artery Disease / surgery*
  • Coronary Vessels / diagnostic imaging
  • Coronary Vessels / injuries
  • Coronary Vessels / pathology
  • Drug-Eluting Stents* / adverse effects
  • Drug-Eluting Stents* / classification
  • Female
  • Humans
  • Intraoperative Complications* / diagnostic imaging
  • Intraoperative Complications* / etiology
  • Intraoperative Complications* / prevention & control
  • Male
  • Outcome Assessment, Health Care
  • Percutaneous Coronary Intervention* / adverse effects
  • Percutaneous Coronary Intervention* / instrumentation
  • Percutaneous Coronary Intervention* / methods
  • Plaque, Atherosclerotic / diagnostic imaging
  • Sirolimus / analogs & derivatives
  • Sirolimus / pharmacology
  • Tomography, Optical Coherence / methods*
  • Vascular System Injuries* / diagnostic imaging
  • Vascular System Injuries* / etiology
  • Vascular System Injuries* / prevention & control

Substances

  • Biodegradable Plastics
  • umirolimus
  • Sirolimus

Associated data

  • ClinicalTrials.gov/NCT03026465